{"id":11793,"date":"2023-04-26T09:48:49","date_gmt":"2023-04-26T07:48:49","guid":{"rendered":"https:\/\/ggba.swiss\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/"},"modified":"2023-07-04T13:44:18","modified_gmt":"2023-07-04T11:44:18","slug":"retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/","title":{"rendered":"RetinAI s&rsquo;associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes"},"content":{"rendered":"\n<p>L&rsquo;atrophie g\u00e9ographique est une forme avanc\u00e9e de d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l&rsquo;\u00e2ge (DMLA) et une cause majeure de perte totale de vision, touchant environ 5 millions de personnes dans le monde. Avec la pr\u00e9valence de la GA qui devrait augmenter \u00e0 mesure que la population mondiale vieillit, le besoin de traitements et d&rsquo;outils de diagnostic innovants est plus urgent que jamais.<\/p>\n<p><a href=\"https:\/\/www.retinai.com\/\" target=\"_blank\" rel=\"noopener\">RetinAI<\/a>, cr\u00e9\u00e9e d\u00e9but 2017 \u00e0 Berne, est une pionni\u00e8re dans le d\u00e9veloppement de solutions logicielles utilisant l&rsquo;apprentissage automatique avanc\u00e9 et la vision par ordinateur pour acc\u00e9l\u00e9rer les processus cliniques, de recherche et pharmaceutiques en ophtalmologie. La plateforme Discovery de la start-up, qui a re\u00e7u la certification 510(k) de la U.S. Food and Drug Administration (FDA) et le marquage CE, permet aux professionnels de la sant\u00e9 de collecter, organiser et analyser les donn\u00e9es sur la sant\u00e9 oculaire pour une prise de d\u00e9cision plus rapide et \u00e9clair\u00e9e.<\/p>\n<h4>Une collaboration strat\u00e9gique pour le traitement des maladies r\u00e9tiniennes<\/h4>\n<p>RetinAI a conclu une collaboration strat\u00e9gique avec <a href=\"https:\/\/www.boehringer-ingelheim.ch\/fr\" target=\"_blank\" rel=\"noopener\">Boehringer Ingelheim<\/a>, un leader dans le d\u00e9veloppement de traitements innovants et plus pr\u00e9cis et l&rsquo;application des technologies num\u00e9riques dans les maladies r\u00e9tiniennes. Dans le cadre de cet accord, RetinAI testera ses outils d&rsquo;IA en analysant les ensembles de donn\u00e9es d&rsquo;imagerie de Boehringer Ingelheim provenant d&rsquo;\u00e9tudes cliniques et de preuves du monde r\u00e9el. L&rsquo;objectif est d&rsquo;identifier de nouveaux biomarqueurs et pr\u00e9dicteurs de la progression de la maladie qui pourraient acc\u00e9l\u00e9rer le d\u00e9veloppement de traitements indispensables.<\/p>\n<p>En int\u00e9grant des technologies num\u00e9riques avanc\u00e9es et l&rsquo;IA, ce partenariat pourrait permettre des diagnostics plus pr\u00e9coces et plus pr\u00e9cis, soutenant la vision de Boehringer Ingelheim de pr\u00e9venir la perte de vision et la c\u00e9cit\u00e9 caus\u00e9es par les maladies r\u00e9tiniennes. En contrepartie de l&rsquo;acc\u00e8s \u00e0 ses services et produits, RetinAI recevra une compensation de la part de Boehringer Ingelheim.<\/p>\n<p>Carlos Ciller, CEO de RetinAI, s&rsquo;est montr\u00e9 optimiste quant \u00e0 cette collaboration, d\u00e9clarant : \u00ab\u00a0Notre plateforme Discovery et nos nouveaux outils d&rsquo;IA en GA acc\u00e9l\u00e8rent la recherche et fournissent des informations solides sur les maladies. Nous sommes convaincus que cette collaboration avec Boehringer Ingelheim peut ouvrir la voie \u00e0 de nouveaux traitements mieux adapt\u00e9s \u00e0 la maladie d&rsquo;un patient, transformant la vie des personnes vivant avec des maladies r\u00e9tiniennes.\u00a0\u00bb<\/p>\n<p>Cette collaboration entre RetinAI et Boehringer Ingelheim marque une \u00e9tape importante dans la lutte contre les maladies r\u00e9tiniennes et souligne le potentiel des technologies de pointe telles que l&rsquo;intelligence artificielle pour am\u00e9liorer la prise en charge des patients et acc\u00e9l\u00e9rer la recherche dans ce domaine en constante \u00e9volution.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La start-up bernoise RetinAI Medical, pionni\u00e8re dans les logiciels de gestion des donn\u00e9es cliniques et d&rsquo;imagerie ainsi que les analyses avanc\u00e9es utilisant l&rsquo;IA pour l&rsquo;ophtalmologie, s&rsquo;est associ\u00e9e \u00e0 Boehringer Ingelheim pour am\u00e9liorer les r\u00e9sultats des patients atteints d&rsquo;atrophie g\u00e9ographique (GA).<\/p>\n","protected":false},"author":3,"featured_media":11794,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1016,1033,1095,1069],"class_list":["post-11793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-artificial-intelligence-fr","tag-digital-health-fr","tag-imaging-fr","tag-pharma-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RetinAI s&#039;associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RetinAI s&#039;associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"La start-up bernoise RetinAI Medical, pionni\u00e8re dans les logiciels de gestion des donn\u00e9es cliniques et d&#039;imagerie ainsi que les analyses avanc\u00e9es utilisant l&#039;IA pour l&#039;ophtalmologie, s&#039;est associ\u00e9e \u00e0 Boehringer Ingelheim pour am\u00e9liorer les r\u00e9sultats des patients atteints d&#039;atrophie g\u00e9ographique (GA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T07:48:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:44:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"RetinAI s&rsquo;associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes\",\"datePublished\":\"2023-04-26T07:48:49+00:00\",\"dateModified\":\"2023-07-04T11:44:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/\"},\"wordCount\":481,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg\",\"keywords\":[\"Artificial Intelligence\",\"Digital Health\",\"Imaging\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/\",\"name\":\"RetinAI s'associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg\",\"datePublished\":\"2023-04-26T07:48:49+00:00\",\"dateModified\":\"2023-07-04T11:44:18+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RetinAI s&rsquo;associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RetinAI s'associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/","og_locale":"fr_FR","og_type":"article","og_title":"RetinAI s'associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes - Greater Geneva Bern area","og_description":"La start-up bernoise RetinAI Medical, pionni\u00e8re dans les logiciels de gestion des donn\u00e9es cliniques et d'imagerie ainsi que les analyses avanc\u00e9es utilisant l'IA pour l'ophtalmologie, s'est associ\u00e9e \u00e0 Boehringer Ingelheim pour am\u00e9liorer les r\u00e9sultats des patients atteints d'atrophie g\u00e9ographique (GA).","og_url":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-04-26T07:48:49+00:00","article_modified_time":"2023-07-04T11:44:18+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"RetinAI s&rsquo;associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes","datePublished":"2023-04-26T07:48:49+00:00","dateModified":"2023-07-04T11:44:18+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/"},"wordCount":481,"image":{"@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg","keywords":["Artificial Intelligence","Digital Health","Imaging","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/","url":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/","name":"RetinAI s'associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg","datePublished":"2023-04-26T07:48:49+00:00","dateModified":"2023-07-04T11:44:18+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/RetinAI-Boehringer-Ingelheim-630x380-1-2.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/retinai-sassocie-a-boehringer-ingelheim-pour-ameliorer-le-traitement-des-maladies-retiniennes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"RetinAI s&rsquo;associe \u00e0 Boehringer Ingelheim pour am\u00e9liorer le traitement des maladies r\u00e9tiniennes"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=11793"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11793\/revisions"}],"predecessor-version":[{"id":18361,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11793\/revisions\/18361"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/11794"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=11793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=11793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=11793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}